PARSIPPANY, NJ--(Marketwire - May 15, 2009) - The Medicines Company (NASDAQ: MDCO) is scheduled to participate in the Deutsche Bank Health Care Conference on Monday, May 18th, 2009. Clive Meanwell, Chairman and Chief Executive Officer, will present at 10am Eastern Time. A company overview and outlook will be provided in the presentation.
The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment
of critical care patients through the delivery of innovative,
cost-effective medicines to the worldwide hospital marketplace. The Company
markets Angiomax® (bivalirudin) in the United States and other countries
for use in patients undergoing coronary angioplasty, and Cleviprex®
(clevidipine butyrate) injectable emulsion in the United States for the
reduction of blood pressure when oral therapy is not feasible or not
desirable. The Company also has an investigational antiplatelet agent,
cangrelor, in late-stage development and a serine protease inhibitor,
CU2010, in early-stage development. Through the acquisition of Targanta
Therapeutics, The Medicines Company's pipeline also includes oritavancin, a
semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory
approval. The Medicines Company's website is www.themedicinescompany.com.
